Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782574 · ClinicalTrials.gov registry record · Phase 1
Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT00782574 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 57 participants.
The verdict
NCT00782574, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
A Phase I study to assess the safety and tolerability of AZD2281 in combination with Cisplatin in patients with advanced Solid Tumours. This is an open label-dose finding; to establish the maximum tolerated dose of AZD2281 combined with Cisplatin in patients with advanced solid tumours. Approximately 50 (max 60) patients from 2 countries will be enrolled
Interventions
- DRUG Cisplatin
- DRUG AZD2281
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2008-11-12 |
| Est. Completion | 2023-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782574
The ClinicalTrials.gov registry entry for NCT00782574 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT00782574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782574 about?
NCT00782574 is a clinical study titled "Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients". A Phase I study to assess the safety and tolerability of AZD2281 in combination with Cisplatin in patients with advanced Solid Tumours. This is an open label-dose finding; to establish the maximum tolerated dose of AZD2281 combined with Cisplatin in patients with advanced solid tumours. Approximatel...
What is the current status of trial NCT00782574?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2008-11-12. Estimated completion is 2023-12-07.
What interventions are being tested in trial NCT00782574?
The interventions under investigation include: Cisplatin (DRUG), AZD2281 (DRUG).
Who is sponsoring clinical trial NCT00782574?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.